The model would adjust Medicare payment for Part B physician-administered drugs based on the lowest prices of that drug in other countries.
The original model was set to roll out at the start of 2021, but was blocked by a U.S. District Court.
CMS received over 1,100 comments on the model, with many agreeing about its mission to combat prescription drug pricing but also expressing concerns over a Jan. 1, 2021, rollout date, according to the document.
